VIPoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
(Mahshid) |
||
Line 19: | Line 19: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] |
Revision as of 17:39, 27 November 2017
VIPoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
VIPoma medical therapy On the Web |
American Roentgen Ray Society Images of VIPoma medical therapy |
Risk calculators and risk factors for VIPoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Initial treatment in patient with VIPoma is prompt replacement of fluid and electrolyte losses. Steroids may be used to provide symptomatic relief.[1]
Medical Therapy
- Initial treatment in patient with VIPoma is prompt replacement of fluid and electrolyte losses.
- Sandostatin or chemotherapy must be considered for malignant tumors.
- Steroids may be used to provide symptomatic relief.
- Prostaglandin synthesis inhibitors (e.g., indomethacin), phenothiazines, and lithium combination may be used.
- Long-term octreotide treatment not only controls the diarrhea in the patients with VIPoma but also may cause arrest or regression of the tumor.
References
- ↑ Vinik A. Vasoactive Intestinal Peptide Tumor (VIPoma) [Updated 2013 Nov 28]. In: De Groot LJ, Beck-Peccoz P, Chrousos G, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278960/